Nissay Asset Management Corp Gilead Sciences, Inc. Transaction History

Nissay Asset Management Corp

$15.5 Billion
Q3 2024

A detailed history of Nissay Asset Management Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nissay Asset Management Corp holds 270,234 shares of GILD stock, worth $24.9 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

270,234

Previous 249,023 8.52%

Holding current value

$24.9 Million

Previous $17.1 Million 32.58%

% of portfolio

0.15%

Previous 0.11%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $1.41 Million - $1.78 Million	21,211 Added 8.52%	270,234 $22.7 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $1.71 Million - $1.97 Million	27,046 Added 12.18%	249,023 $17.1 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $3.52 Million - $4.29 Million	49,153 Added 28.44%	221,977 $16.3 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $1.03 Million - $1.17 Million	14,049 Added 8.85%	172,824 $14 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $732,819 - $799,520	9,911 Added 6.66%	158,775 $11.9 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $53,891 - $61,470	-709 Reduced 0.47%	148,864 $11.5 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $371,165 - $422,872	-4,801 Reduced 3.11%	149,573 $12.4 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $83,945 - $120,516	1,347 Added 0.88%	154,374 $13.3 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $334,436 - $382,012	5,617 Added 3.81%	153,027 $9.44 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $34,978 - $39,396	606 Added 0.41%	147,410 $9.11 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $159,164 - $199,449	2,748 Added 1.91%	146,804 $8.73 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $206,448 - $234,322	3,182 Added 2.26%	144,056 $10.5 Million
Q3 2021 Nov 10, 2021	SELL	$67.69 - $73.03 $251,671 - $271,525	-3,718 Reduced 2.57%	140,874 $9.84 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $181,524 - $198,340	2,860 Added 2.02%	144,592 $9.96 Million
Q1 2021 May 11, 2021	SELL	$60.0 - $68.46 $240,900 - $274,866	-4,015 Reduced 2.75%	141,732 $9.16 Million
Q4 2020 Feb 08, 2021	SELL	$56.65 - $64.55 $399,949 - $455,723	-7,060 Reduced 4.62%	145,747 $8.49 Million
Q3 2020 Oct 20, 2020	SELL	$62.1 - $78.08 $1.33 Million - $1.67 Million	-21,444 Reduced 12.31%	152,807 $9.66 Million
Q2 2020 Jul 27, 2020	BUY	$72.34 - $84.0 $593,766 - $689,472	8,208 Added 4.94%	174,251 $13.4 Million
Q1 2020 May 05, 2020	BUY	$62.63 - $80.22 $65,698 - $84,150	1,049 Added 0.64%	166,043 $12.4 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $363,742 - $400,105	-5,903 Reduced 3.45%	164,994 $10.7 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $337,303 - $372,324	5,396 Added 3.26%	170,897 $10.8 Million
Q2 2019 Aug 07, 2019	SELL	$61.87 - $69.38 $403,083 - $452,010	-6,515 Reduced 3.79%	165,501 $11.2 Million
Q1 2019 May 03, 2019	SELL	$62.53 - $70.05 $498,051 - $557,948	-7,965 Reduced 4.43%	172,016 $11.2 Million
Q4 2018 Feb 06, 2019	SELL	$60.54 - $79.0 $98,922 - $129,086	-1,634 Reduced 0.9%	179,981 $11.3 Million
Q3 2018 Oct 30, 2018	SELL	$71.28 - $78.92 $2.14 Million - $2.37 Million	-30,076 Reduced 14.21%	181,615 $14 Million
Q2 2018 Aug 08, 2018	SELL	$64.88 - $75.68 $2.21 Million - $2.58 Million	-34,131 Reduced 13.88%	211,691 $15 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $1.62 Million - $1.98 Million	-22,283 Reduced 8.31%	245,822 $18.5 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $19.1 Million - $22.4 Million	268,105	268,105 $19.2 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $115B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.

Account

Nissay Asset Management Corp Gilead Sciences, Inc. Transaction History